Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 3Anemia, Refractory, with Excess of Blasts 3Leukemia 2Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Anemia, Refractory 1

Interventions

Cyclophosphamide 22fludarabine phosphate 18Busulfan 16Antilymphocyte Serum 15Radiotherapy 12Cyclosporine 11Cord Blood Stem Cell Transplantation 11Peripheral Blood Stem Cell Transplantation 10Melphalan 10Filgrastim 10Tacrolimus 9Mycophenolic Acid 9Methylprednisolone 9Methotrexate 9Etoposide 7Cytarabine 7Whole-Body Irradiation 6sargramostim 4Tretinoin 3Thalidomide 3Carboplatin 3venetoclax 2ruxolitinib 2Thiotepa 2Thioguanine 2Specimen Handling 2Sirolimus 2Rituximab 2Leucovorin 2Immunoenzyme Techniques 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × Amifostine × Classical hematology × Clear all
NCT00098683 2014-02-13

Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes

Children's Oncology Group

Phase 2 Completed
10 enrolled
Classical hematologyMyeloid

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡